Cargando…
安罗替尼治疗KRAS突变型晚期肺腺癌1例
In recent years, the number of advanced non-small cell lung cancer (NSCLC) patients has gradually increased, and the treatment methods have also been significantly increased. However, there are no standard treatment plans at home and abroad for third-line and above patients who are refractory to tar...
Formato: | Online Artículo Texto |
---|---|
Lenguaje: | English |
Publicado: |
中国肺癌杂志编辑部
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5999919/ https://www.ncbi.nlm.nih.gov/pubmed/29764596 http://dx.doi.org/10.3779/j.issn.1009-3419.2018.05.13 |
Ejemplares similares
-
帕博利珠单抗联合安罗替尼四线治疗EGFR基因敏感突变阳性肺腺癌1例
Publicado: (2021) -
厄洛替尼治疗脑脊液检测EGFR敏感突变的肺腺癌一例
Publicado: (2016) -
不同机制所致的血管紊乱化生长的共同干预——安罗替尼治疗右肺鳞癌合并血栓闭塞性脉管炎1例
Publicado: (2020) -
高级别胎儿型肺腺癌1例
Publicado: (2019) -
吉非替尼致急性肺损伤——附1例报道
Publicado: (2011)